GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » Price-to-Funds-From-Operations

Redhill Biopharma (XTAE:RDHL) Price-to-Funds-From-Operations : (As of Apr. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Redhill Biopharma (XTAE:RDHL) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.